key: cord-0708683-tkfhg8f6
authors: Patel, Priyanka D.; Patel, Pratiksha; Liang, Yuanyuan; Meiring, James E.; Misiri, Theresa; Mwakiseghile, Felistas; Tracy, J. Kathleen; Masesa, Clemens; Msuku, Harrison; Banda, David; Mbewe, Maurice; Henrion, Marc; Adetunji, Fiyinfolu; Simiyu, Kenneth; Rotrosen, Elizabeth; Birkhold, Megan; Nampota, Nginache; Nyirenda, Osward M.; Kotloff, Karen; Gmeiner, Markus; Dube, Queen; Kawalazira, Gift; Laurens, Matthew B.; Heyderman, Robert S.; Gordon, Melita A.; Neuzil, Kathleen M.
title: Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children
date: 2021-09-16
journal: N Engl J Med
DOI: 10.1056/nejmoa2035916
sha: e6f7266e98444500952433cf29d9534cb0803709
doc_id: 708683
cord_uid: tkfhg8f6

BACKGROUND: Typhoid fever caused by multidrug-resistant H58 Salmonella Typhi is an increasing public-health threat in sub-Saharan Africa. We present phase 3 efficacy data from an African trial of a Vi-polysaccharide typhoid conjugate vaccine (Vi-TCV). METHODS: Children aged 9 months to 12 years in Blantyre, Malawi were randomized (1:1) in a double-blind trial to receive Vi-TCV (single dose) or group-A meningococcal control vaccine (MenA).The primary outcome was blood culture-confirmed typhoid fever. We present the primary vaccine efficacy (VE) and safety outcomes after 18–24 months of follow-up. RESULTS: This intention-to-treat (ITT) analysis included 28,130 children, comprising 14,069 children who received Vi-TCV and 14,061 children who received MenA. Blood culture-confirmed typhoid fever occurred in 12 children in the Vi-TCV group (46.9 per 100,000 person-years) and 62 children in the MenA group (243 per 100,000 person-years). Overall VE was 80.7% (95% confidence interval (CI): 64.2% to 89.6%) in an ITT analysis, and 83.7% (95% CI: 68.1%−91.6%) in a per-protocol analysis. In total, 130 serious adverse events occurred in the first 6 months after vaccination (52 in Vi-TCV group and 78 in MenA group), including 6 deaths (all in MenA group). No serious adverse event was considered by the investigator as related to study vaccination. CONCLUSIONS: Vi-TCV reduced blood culture-confirmed typhoid fever among Malawian children aged 9 months to 12 years. (Funded by the Bill & Melinda Gates Foundation; ClinicalTrials.gov number NCT03299426.)

. Kaplan Meier showing the cumulative incidence of typhoid fever by age group .

The trial vaccine, Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar TCV®, Bharat Biotech, Hyderabad, India) consists of Vi polysaccharide conjugated to a tetanus toxoid protein carrier 1 (25 µg per 0.5 ml dose). Vi-TCV was available as a 2.5 ml 5-dose vial with each 0.5 ml vaccine dose containing purified Vi-capsular polysaccharide of S. Typhi Ty2 conjugated to 25 mcg tetanus toxoid. Meningococcal capsular Group A conjugate vaccine (MenA, MenAfriVac, Serum Institute of India PVT Ltd) was given to children aged ≥1 year at a dose of 10 µg per 0.5 ml and 5 µg per 0. 5ml to children aged <1 year.

Vaccines were administered intramuscularly in the left thigh (children aged <1 year) or left arm (children aged ≥ 1 year). Both Vi-TCV and MenA were co-administered with the routine measles-rubella vaccine (in the right thigh) in children aged 9-11 months (Malawi Expanded Programme on Immunization).

1.2 Methods S1. Inclusion and exclusion criteria 1.2.1 Inclusion criteria 2

• Healthy male or female child at least 9 months of age and no older than 12 years and 364 days at the time of vaccination.

• Child whose parent or guardian resides within the study areas; Ndirande and Zingwangwa at the time of vaccination and who intends to be present in the area for the duration of the trial.

• A child whose parent or guardian has voluntarily given informed consent.

• History of documented hypersensitivity to any component of the vaccine.

• Prior receipt of any typhoid vaccine in the past 3 years.

• History of severe allergic reaction with generalized urticarial, angioedema, or anaphylaxis.

• Any condition determined by the investigator likely to interfere with evaluation of the vaccine or to be a significant potential health risk to the child or make it unlikely that the child would complete the study.

The following were temporary contraindications to enrollment and vaccination. If these applied, the participant was temporarily excluded from vaccination until 48 hours passed. A reassessment was done to ensure these temporary exclusion criteria no longer existed:

• Reported fever within 24 hours before vaccination.

• Use of antipyretics within 4 hours before vaccination.

An adverse event was defined as any untoward medical occurrence in a participant to whom Vi-TCV or MCV-A has been administered, including occurrences that are not necessarily caused by or related to the vaccine. The following adverse events were documented: fever, injection site pain, swelling, tenderness, erythema, myalgia, and arthralgia.

A serious adverse event was defined as any untoward medical occurrence that results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability. Figure S1 . Kaplan Meier showing the cumulative incidence of typhoid fever by age group 

Supplementary appendix Figure S1 . Kaplan-Meier Estimates the Cumulative Incidence of Blood Culture-Positive Typhoid fever by Vaccine Group and Age Group, Intention to Treat Population. Blood culture-positive typhoid fever was the primary outcome

Typhoid vaccines: WHO position paper

Typhoid vaccine acceleration consortium Malawi: A Phase III, randomized, double-blind, controlled trial of the clinical efficacy of typhoid conjugate vaccine among children in